糖尿病性视网膜病变（DR）和糖尿病性黄斑水肿（DME）是糖尿病患者常见的微血管并发症，这可能 会给视力造成突发性损害及视力衰弱，最终会导致失明。DME是DR常见的一种表现，也是DR患者视力 丧失的主要原因。DME是由视网膜微血管变化产生的。基底膜增厚和周细胞的数量减少会导致视网膜 血管通透性增加及功能丧失。血液-视网膜屏障的这种改变导致血浆成分渗漏到视网膜的周围，引起视 网膜水肿。SQ-129玻璃体缓释注射液是沈阳兴齐眼药股份有限公司研发的玻璃体注射液，适应症为治 疗成年患者的糖尿病性黄斑水肿（DME）。SQ-129玻璃体缓释注射液糖尿病性黄斑水肿（DME）Ⅰ/Ⅱ 期试验的主要目的是探索SQ-129玻璃体缓释注射液用于糖尿病性黄斑水肿（DME）的安全性和初步疗 效，为后续临床研究方案设计提供依据。以及探索其药代动力学特征。 格隆汇2月3日丨兴齐眼药(300573.SZ)在投资者互动平台表示，公司研发的SQ-129玻璃体缓释注射液于 今日完成了"一项评估SQ-129玻璃体缓释注射液治疗糖尿病性黄斑水肿的安全性、药代动力学特征和初 步疗效的Ⅰ/Ⅱ期临床试验"首例受试者入组，正式进入Ⅰ/Ⅱ期临床试验。 ...

关于SQ-129玻璃体缓释注射液用于糖尿病性黄斑水肿 Ⅰ/Ⅱ期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-129玻璃体缓 释注射液于今日完成了"一项评估SQ-129玻璃体缓释注射液治疗糖尿病性黄斑 水肿的安全性、药代动力学特征和初步疗效的Ⅰ/Ⅱ期临床试验"首例受试者入 组，正式进入Ⅰ/Ⅱ期临床试验。现将有关内容公告如下： 一、基本情况 药物名称：SQ-129玻璃体缓释注射液 注册分类：化学药品2.2类 剂型：注射液 证券代码：300573 证券简称：兴齐眼药 公告编号：2026-005 沈阳兴齐眼药股份有限公司 SQ-129玻璃体缓释注射液糖尿病性黄斑水肿（DME）Ⅰ/Ⅱ期试验的主要目的 是探索SQ-129玻璃体缓释注射液用于糖尿病性黄斑水肿（DME）的安全性和初步 疗效，为后续临床研究方案设计提供依据。以及探索其药代动力学特征。 1 三、同类药品的情况 截至本公告披露日，目前国内外尚无该产品获批上市。 四、对公司的影响 SQ-129玻璃体缓释注射液糖尿病性黄斑水肿（DM ...

证券日报网讯 2月2日，兴齐眼药在互动平台回答投资者提问时表示，公司新闻内容为0.02%硫酸阿托品 滴眼液（兴齐®美欧品®）在沈阳棋盘山工厂进行的首发仪式，标志着我国首款获批用于延缓儿童近视 进展的0.02%浓度硫酸阿托品滴眼液正式投入临床使用，进一步丰富了临床治疗选择。公司一季度业绩 数据请关注后续披露的2026年第一季度报告。 （文章来源：证券日报） ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-004 沈阳兴齐眼药股份有限公司 关于SQ-129玻璃体缓释注射液用于视网膜分支静脉阻塞（BRVO） 或中央静脉阻塞（CRVO）引起的黄斑水肿Ⅰ/Ⅱ期临床试验 首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-129玻璃体缓 释注射液于今日完成了"一项评估SQ-129玻璃体缓释注射液用于视网膜分支静 脉阻塞（BRVO）或中央静脉阻塞（CRVO）引起的黄斑水肿的安全性、药代动力 学特征和初步疗效的Ⅰ/Ⅱ期临床试验"首例受试者入组，正式进入Ⅰ/Ⅱ期临 床试验。现将有关内容公告如下： 一、基本情况 药物名称：SQ-129玻璃体缓释注射液 注册分类：化学药品2.2类 1 治疗成年患者中由视网膜分支静脉阻塞（BRVO）或中央静脉阻塞（CRVO）引起的 黄斑水肿。 SQ-129玻璃体缓释注射液BRVO或CRVO引起的黄斑水肿Ⅰ/Ⅱ期试验的主要目 的是探索SQ-129玻璃体缓释注射液用于视网膜分支静脉阻塞（BRVO）或中央静脉 阻塞（C ...

Core Viewpoint - The company emphasizes a cautious approach in its earnings forecast, adhering to regulations that limit the range of performance predictions to within 50%, with encouragement to keep it under 30% [1] Group 1: Earnings Forecast - The company has set a narrower performance range than the regulatory maximum, reflecting its prudent operational strategy [1] - The company aims to communicate its investment value to the market through steady operations and fulfilling information disclosure obligations [1] Group 2: Business Strategy - The company focuses on its core business and enhances research and innovation to continuously improve operational performance [1] - The commitment is to create long-term and stable value returns for shareholders [1]

Group 1 - The core viewpoint of the news is that Xingqi Eye Pharmaceutical has shown fluctuations in its stock price and significant growth in revenue and profit for the year 2025 [1][2] Group 2 - As of January 28, Xingqi Eye Pharmaceutical's stock price increased by 2.06% to 72.70 CNY per share, with a total market capitalization of 17.915 billion CNY [1] - The company experienced a net inflow of main funds amounting to 31.14 million CNY, with large orders accounting for 26.03% of purchases [1] - Year-to-date, the stock price has risen by 3.43%, but it has seen a decline of 12.11% over the last five trading days [1] Group 3 - For the period from January to September 2025, Xingqi Eye Pharmaceutical achieved a revenue of 1.904 billion CNY, representing a year-on-year growth of 32.27%, and a net profit of 599 million CNY, which is a 105.98% increase [2] - The company has distributed a total of 1.166 billion CNY in dividends since its A-share listing, with 985 million CNY distributed over the past three years [2] - As of September 30, 2025, the number of shareholders increased by 16.85% to 54,100, while the average circulating shares per person decreased by 14.42% to 3,480 shares [2]

Group 1 - The company emphasizes the importance of investor relations management and actively communicates its investment value to the market [1] - The company is committed to steady operations and fulfilling information disclosure obligations [1] - The company aims to provide continuous and stable cash dividends to return value to investors [1]

Group 1 - The core point of the news is that Xingqi Eye Pharmaceutical experienced a decline of 5.58% in its stock price, reaching 73.99 CNY per share, with a trading volume of 510 million CNY and a turnover rate of 3.57%, resulting in a total market capitalization of 18.233 billion CNY [1] - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, is located in Shenyang, Liaoning Province, and specializes in the research, production, and sales of ophthalmic drugs [1] - The company's main business revenue composition includes eye drops at 82.15%, gel/eye ointments at 16.70%, and other supplementary products at 1.15% [1] Group 2 - From the perspective of major circulating shareholders, Southern Fund's Southern CSI 500 ETF (510500) reduced its holdings by 10,000 shares in the third quarter, now holding 2.5063 million shares, which accounts for 1.33% of the circulating shares [2] - The estimated floating loss for Southern CSI 500 ETF today is approximately 10.9525 million CNY [2] - The Southern CSI 500 ETF, established on February 6, 2013, has a latest scale of 144.69 billion CNY, with a year-to-date return of 12.39% and a one-year return of 52.22% [2]

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]